Sam-il Pharmaceutical Signs MOU with KC Pharmaceuticals for North American Distribution of Eye Drops
Sam-il Pharmaceutical has signed a memorandum of understanding (MOU) with KC Pharmaceuticals, a U.S.-based ophthalmology specialty pharmaceutical company, to expand its presence in the North American market. The strategy is to accelerate entry into the U.S. market through collaboration with the largest private brand (PB) eye drop manufacturer in North America.
On May 22, Sam-il Pharmaceutical announced that it had signed a business agreement with KC Pharmaceuticals, headquartered in Pomona, California, for North American distribution and business cooperation.
KC Pharmaceuticals, founded in 1987, is an ophthalmology specialty pharmaceutical company specializing in the manufacturing of eye drops and contact lens care products. It is recognized as one of the largest PB eye drop manufacturers in North America, supplying dry eye treatments, artificial tears, decongestants, and allergy eye drops to major U.S. retail and pharmacy chains such as Walmart, CVS, Walgreens, Target, and Kroger.
Through this agreement, the two companies have agreed to prioritize discussions on the North American distribution of Sam-il Pharmaceutical’s "Eye Two O Mini" eye drops. They also plan to jointly review potential cooperation in various fields, including product supply, local commercialization, distribution, and business development.
Sam-il Pharmaceutical stated that it is accelerating efforts to obtain cGMP certification from the U.S. Food and Drug Administration (FDA) to further expand into the North American market.
Going forward, both companies plan to continue discussions on mid- to long-term cooperation directions, including leveraging their networks and business infrastructure in North America, market expansion strategies, business development collaboration, and building a foundation for local commercialization.
A Sam-il Pharmaceutical representative stated, "We are continuously seeking global cooperation opportunities to expand into the North American market," adding, "With this collaboration, we plan to strengthen our global business competitiveness and actively pursue overseas market expansion."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This MOU is regarded as significant in that Sam-il Pharmaceutical is taking a full-fledged step towards targeting the eye drop market and expanding its global business by partnering with a local specialty company that possesses a North American distribution network.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.